Effects of Chronic Administration of Carteolol on .BETA.-Adrenoceptors in Spontaneously Hypertensive Rat Heart.

DOI PubMed
  • Ebii Koichi
    Department of Neurobiology, Kyoto Pharmaceutical University
  • Fukunaga Reiko
    Department of Neurobiology, Kyoto Pharmaceutical University
  • Taniguchi Takashi
    Department of Neurobiology, Kyoto Pharmaceutical University
  • Fujiwara Motohatsu
    Department of Pharmacology, Faculty of Medicine, Kyoto University Department of Pharmacology, Faculty of Pharmaceutical Sciences, Mukogawa Women's University
  • Nakayama Sunao
    Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.
  • Saitoh Yuichi
    Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.
  • Kimura Yukio
    Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.

Search this article

Abstract

We studied the effects of chronic administration of β-adrenoceptor antagonists with and without intrinsic sympathomimetic activity (ISA): carteolol (with ISA) and propranolol (without ISA), respectively, on the heart of spontaneously hypertensive rat (SHR) and Wistar Kyoto rat (WKY). Six-week-old SHRs and WKYs were orally given carteolol or propranolol for ten weeks. The heart rate was reduced in propranolol-treated SHR, but not in carteolol-treated ones. In WKY, carteolol-treatment increased the heart rate. The number and affinities of β-adrenoceptors were analyzed using [3H]dihydroalprenolol as a ligand. Propranolol at 30 mg/kg increased the number of cardiac β-adrenoceptors in both SHR and WKY. In contrast, 10 mg/kg carteolol significantly decreased the number of cardiac β-adrenoceptors in SHR, but not in WKY. These data indicate that carteolol, a β-adrenoceptor antagonist with ISA, does not cause up-regulation of the number of cardiac β-adrenoceptors in the rat and suggest that this fact is related to a possible lack of “rebound phenomena” after sudden discontinuation of chronic carteolol-therapy in humans.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top